Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text Volltext
DOI
PMC
 |
Free by publisher |
Open Access Green as soon as Postprint is submitted to ZB.
Medical nanoparticles for next generation drug delivery to the lungs.
Eur. Respir. J. 44, 765-774 (2014)
Publ. Version/Full Text Volltext
DOI
PMC
Respiratory diseases are an increasing burden for the ageing population. Although our understanding of these diseases has improved significantly over the past decades, diagnostic and therapeutic options for treating lung diseases, such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and lung cancer, remain limited. Multidisciplinary approaches that bridge the gap between medicinal and materials sciences will likely contribute to promising new therapeutic and diagnostic solutions. One such multidisciplinary approach is the use of nanoparticles as carriers for the delivery of drugs. The advantages of using nanoparticles to deliver drugs include: increased drug concentration at the disease site; minimised drug degradation and loss; ease of creating inhalable formulations; and the possibility of specific cell targeting. This article gives a brief overview on the emerging field of nanocarriers as drug delivery vehicles for the treatment of lung diseases.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Solid Lipid Nanoparticles; Liposomal Dry Powder; Cystic-fibrosis; Targeted Delivery; Gene-therapy; In-vitro; Alveolar Macrophages; Clinical-evaluation; Endothelial-cells; Folate Receptor
ISSN (print) / ISBN
0903-1936
e-ISSN
1399-3003
Journal
European Respiratory Journal
Quellenangaben
Volume: 44,
Issue: 3,
Pages: 765-774
Publisher
European Respiratory Society
Publishing Place
Sheffield
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Lung Health and Immunity (LHI)